What sense lies in antisense inhibition of inducible nitric oxide synthase expression?

被引:10
作者
Hemmrich, K
Kröncke, KD
Suschek, CV
Kolb-Bachofen, V
机构
[1] Univ Dusseldorf, Res Grp Immunobiol, D-40001 Dusseldorf, Germany
[2] Univ Dusseldorf, Dept Biochem & Mol Biol 1, D-40001 Dusseldorf, Germany
来源
NITRIC OXIDE-BIOLOGY AND CHEMISTRY | 2005年 / 12卷 / 04期
关键词
antisense technique; oligonucleotides; inducible nitric oxide synthase; nitric oxide; transfection; liposomes;
D O I
10.1016/j.niox.2005.04.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The impact of nitric oxide (NO) synthesized after activation by proinflammatory cytokines and/or bacterial products by an inducible NO synthase (iNOS) is still contradictory. Expression of iNOS in inflammatory reactions is often found predominantly in cells of epithelial origin, and in these cases NO may serve as a protective agent limiting pathogen spreading, downregulating local inflammatory reactions by inducing production of Th2-like responses in a classical feedback circle, or limiting tissue damage during stress conditions. However, an abundant amount of data on chronic human disorders with predominant proinflammatory Th1-like reactions points to a destructive role of iNOS activity calling for a specific inhibition. Various methods to inhibit iNOS have been established to elucidate a protective versus a destructive role of NO during various stresses. In this review, we focus on antisense (AS)-mediated gene knock-down as a relatively new method to inhibit NO production and summarize the techniques applied and their successes. At least in theory, it provides a specific, rapid, and potentially high-throughput method for inhibiting gene expression and function. We here discuss the opportunities of iNOS-directed AS-ODN, and extensively deal with limitations and experimental problems. © 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:183 / 199
页数:17
相关论文
共 175 条
[1]   Targeting of iNOS with antisense DNA plasmid reduces cytokine-induced inhibition of osteoblastic activity [J].
Abe, T ;
Hikiji, H ;
Shin, WS ;
Koshikiya, N ;
Shima, S ;
Nakata, J ;
Susami, T ;
Takato, T ;
Toyo-oka, T .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 285 (03) :E614-E621
[2]   A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma [J].
Advani, R ;
Peethambaram, P ;
Lum, BL ;
Fisher, GA ;
Hartmann, L ;
Long, HJ ;
Halsey, J ;
Holmlund, JT ;
Dorr, A ;
Sikic, BI .
CANCER, 2004, 100 (02) :321-326
[3]   NITRIC-OXIDE AND PROSTANOIDS PROTECT THE RENAL OUTER MEDULLA FROM RADIOCONTRAST TOXICITY IN THE RAT [J].
AGMON, Y ;
PELEG, H ;
GREENFELD, Z ;
ROSEN, S ;
BREZIS, M .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (03) :1069-1075
[4]  
Agrawal Sudhir, 1995, Current Opinion in Biotechnology, V6, P12, DOI 10.1016/0958-1669(95)80003-4
[5]   Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? [J].
Alayash, AI .
NATURE BIOTECHNOLOGY, 1999, 17 (06) :545-549
[6]   Nitric oxide synthases: structure, function and inhibition [J].
Alderton, WK ;
Cooper, CE ;
Knowles, RG .
BIOCHEMICAL JOURNAL, 2001, 357 (03) :593-615
[7]   Advances in follicular lymphoma [J].
Archuleta, TD ;
Armitage, JO .
SEMINARS IN ONCOLOGY, 2004, 31 (02) :66-71
[8]   Specific inhibition of nitric oxide production in macrophages by phosphorothioate antisense oligonucleotides [J].
Arima, H ;
Sakamoto, T ;
Aramaki, Y ;
Ishidate, K ;
Tsuchiya, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (10) :1079-1084
[9]   Toxicity, uptake kinetics and efficacy of new transfection reagents: Increase of oligonucleotide uptake [J].
Axel, DI ;
Spyridopoulos, I ;
Riessen, R ;
Runge, H ;
Viebahn, R ;
Karsch, KR .
JOURNAL OF VASCULAR RESEARCH, 2000, 37 (04) :221-234
[10]  
Belfort R, 2002, AM J OPHTHALMOL, V133, P467